Do analysts rate ASMB or CPIX?

Assembly Biosciences presently has a consensus target price of $44.00, suggesting a potential upside of 80.03%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Assembly Biosciences (ASMB) Competitors

$24.44 +0.29 (+1.20%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$23.65 -0.79 (-3.23%)

As of 06/18/2026 06:49 PM Eastern

Compare

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

Should you buy Assembly Biosciences stock or one of its competitors? MarketBeat compares Assembly Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assembly Biosciences include Pacira BioSciences (PCRX), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Pacira BioSciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Pacira BioSciences	$726.41M	1.21	$7.03M	$0.12	186.08

Assembly Biosciences presently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Pacira BioSciences has a consensus price target of $29.40, suggesting a potential upside of 31.66%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Assembly Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pacira BioSciences had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Pacira BioSciences and 1 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.97 beat Assembly Biosciences' score of -1.00 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Pacira BioSciences	Positive

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Pacira BioSciences	0.70%	10.24%	5.47%

Summary

Pacira BioSciences beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Omeros?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Omeros currently has a consensus price target of $40.33, suggesting a potential upside of 292.35%. Assembly Biosciences has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Given Omeros' stronger consensus rating and higher probable upside, research analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Omeros had 3 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.16 beat Assembly Biosciences' score of -1.00 indicating that Omeros is being referred to more favorably in the media.

Company	Overall Sentiment
Omeros	Neutral
Assembly Biosciences	Negative

Omeros has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.69
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Summary

Omeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Assembly Biosciences has a net margin of -8.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Assembly Biosciences' return on equity of -4.21% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Assembly Biosciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Cumberland Pharmaceuticals' average media sentiment score of 0.37 beat Assembly Biosciences' score of -1.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Cumberland Pharmaceuticals	Neutral

Assembly Biosciences presently has a consensus target price of $44.00, suggesting a potential upside of 80.03%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Cumberland Pharmaceuticals	$44.52M	1.92	-$2.84M	-$0.49	N/A

Summary

Assembly Biosciences beats Cumberland Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Assembly Biosciences compare to Eli Lilly and Company?

Assembly Biosciences (NASDAQ:ASMB) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Eli Lilly and Company has a net margin of 34.98% compared to Assembly Biosciences' net margin of -8.98%. Eli Lilly and Company's return on equity of 105.77% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Eli Lilly and Company	34.98%	105.77%	23.76%

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Eli Lilly and Company has a consensus price target of $1,227.74, suggesting a potential upside of 11.74%. Given Assembly Biosciences' higher probable upside, equities research analysts plainly believe Assembly Biosciences is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, Eli Lilly and Company had 172 more articles in the media than Assembly Biosciences. MarketBeat recorded 173 mentions for Eli Lilly and Company and 1 mentions for Assembly Biosciences. Eli Lilly and Company's average media sentiment score of 1.00 beat Assembly Biosciences' score of -1.00 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Eli Lilly and Company	Positive

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Assembly Biosciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Eli Lilly and Company	$65.18B	15.88	$20.64B	$28.15	39.03

Summary

Eli Lilly and Company beats Assembly Biosciences on 14 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Johnson & Johnson?

Assembly Biosciences (NASDAQ:ASMB) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Assembly Biosciences has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Johnson & Johnson had 117 more articles in the media than Assembly Biosciences. MarketBeat recorded 118 mentions for Johnson & Johnson and 1 mentions for Assembly Biosciences. Johnson & Johnson's average media sentiment score of 1.33 beat Assembly Biosciences' score of -1.00 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Johnson & Johnson	Positive

Assembly Biosciences presently has a consensus price target of $44.00, indicating a potential upside of 80.03%. Johnson & Johnson has a consensus price target of $253.04, indicating a potential upside of 10.81%. Given Assembly Biosciences' higher possible upside, equities analysts plainly believe Assembly Biosciences is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Johnson & Johnson has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Johnson & Johnson	$94.19B	5.84	$26.80B	$8.65	26.40

Johnson & Johnson has a net margin of 21.83% compared to Assembly Biosciences' net margin of -8.98%. Johnson & Johnson's return on equity of 32.60% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Johnson & Johnson	21.83%	32.60%	13.29%

Summary

Johnson & Johnson beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$383.81M	$5.70B	$6.66B	$12.38B
Dividend Yield	N/A	0.69%	2.68%	5.68%
P/E Ratio	-222.16	7.25	24.50	24.42
Price / Sales	5.37	23.49	573.80	128.85
Price / Cash	N/A	8.19	44.20	55.24
Price / Book	1.87	4.13	10.62	6.58
Net Income	-$6.12M	$99.67M	$3.57B	$337.29M
7 Day Performance	6.45%	0.75%	0.71%	0.60%
1 Month Performance	-7.84%	5.65%	3.94%	5.00%
1 Year Performance	42.59%	122.03%	28.52%	31.05%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	2.0261 of 5 stars	$24.44 +1.2%	$44.00 +80.0%	+42.6%	$383.81M	$72.30M	N/A	100	Negative News
PCRX Pacira BioSciences	4.2089 of 5 stars	$23.36 -0.2%	$29.40 +25.8%	-7.5%	$918.78M	$734.86M	194.60	720
OMER Omeros	3.432 of 5 stars	$10.41 +2.1%	$40.33 +287.4%	+219.3%	$754.87M	$9.89M	14.90	210	Gap Up
CPIX Cumberland Pharmaceuticals	0.7333 of 5 stars	$5.68 +3.6%	N/A	+6.7%	$85.09M	$44.52M	N/A	80
LLY Eli Lilly and Company	4.6038 of 5 stars	$1,167.65 +2.8%	$1,227.74 +5.1%	+40.1%	$1.10T	$65.18B	41.55	50,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

How does Assembly Biosciences compare to Pacira BioSciences?

Summary

How does Assembly Biosciences compare to Omeros?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Summary

How does Assembly Biosciences compare to Johnson & Johnson?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

How does Assembly Biosciences compare to Pacira BioSciences?

Which has preferable earnings and valuation, ASMB or PCRX?

Do analysts prefer ASMB or PCRX?

Which has more volatility & risk, ASMB or PCRX?

Do insiders and institutionals have more ownership in ASMB or PCRX?

Does the media favor ASMB or PCRX?

Is ASMB or PCRX more profitable?

Summary

How does Assembly Biosciences compare to Omeros?

Do analysts prefer OMER or ASMB?

Do institutionals and insiders hold more shares of OMER or ASMB?

Does the media prefer OMER or ASMB?

Which has more volatility and risk, OMER or ASMB?

Which has preferable valuation & earnings, OMER or ASMB?

Is OMER or ASMB more profitable?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Is ASMB or CPIX more profitable?

Which has more risk & volatility, ASMB or CPIX?

Do insiders and institutionals hold more shares of ASMB or CPIX?

Does the media favor ASMB or CPIX?

Do analysts rate ASMB or CPIX?

Which has higher earnings & valuation, ASMB or CPIX?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Is ASMB or LLY more profitable?

Do analysts rate ASMB or LLY?

Does the media prefer ASMB or LLY?

Do insiders & institutionals have more ownership in ASMB or LLY?

Which has more volatility & risk, ASMB or LLY?

Which has better earnings & valuation, ASMB or LLY?

Summary

How does Assembly Biosciences compare to Johnson & Johnson?

Which has more risk and volatility, ASMB or JNJ?

Does the media favor ASMB or JNJ?

Do analysts recommend ASMB or JNJ?

Do insiders and institutionals believe in ASMB or JNJ?

Which has better earnings and valuation, ASMB or JNJ?

Is ASMB or JNJ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools